Golimumab in Axial Spondyloarthritis: Clinical Outcomes Meet Real-World Benefits

Axial spondyloarthritis, a chronic and often debilitating inflammatory disease of the spine and sacroiliac joints, has long forced patients to navigate years of delayed diagnosis, persistent pain, and progressive structural damage before finding an effective therapy. Now, a comprehensive narrative review published in the journal Advances in Therapy has brought together the full arc of evidence for golimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, weaving together pivotal randomized controlled trials, post hoc biomarker analyses, and a decade of real-world registry data into a single, unusually complete picture of how the drug performs both in controlled settings and in the messy reality of routine clinical care.

The review, led by Atul Deodhar of Oregon Health and Science University together with Tae-Jong Kim, Victoria Navarro-Compán, Sofia Ramiro, and colleagues, arrives at a moment when the terminology and classification of the disease itself have just been overhauled. In 2024, the Assessment of SpondyloArthritis International Society retired the term ankylosing spondylitis in favor of axial spondyloarthritis, a label that now covers both radiographic disease, in which sacroiliac joint damage is visible on X-rays, and non-radiographic disease, where changes are detectable only on more sensitive imaging such as MRI. An analysis of eight cohorts underpinning that change found a striking overlap between the old and new patient populations: 93 percent of patients meeting the modified New York criteria for ankylosing spondylitis also met the ASAS criteria for radiographic axial spondyloarthritis, and 96 percent did so in the reverse direction. The practical consequence, the review notes, is that results from decades of ankylosing spondylitis trials can be directly compared with modern studies of radiographic axial spondyloarthritis, allowing a drug like golimumab to be evaluated across an unusually long evidence timeline.

Golimumab’s mechanism of action sits at the center of the disease’s inflammatory machinery. The antibody, produced by a recombinant cell line and originally derived from genetically modified mice immunized with human TNF-alpha, binds with high affinity to both the soluble and transmembrane bioactive forms of human TNF-alpha, preventing the cytokine from engaging its receptors. This neutralization dampens inflammation, tissue damage, and specific immune functions, and like other TNF inhibitors containing comparable constant region components, golimumab also triggers complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, reverse signaling, and broad cytokine suppression. The drug is available as a once-monthly subcutaneous injection and as an intravenous formulation given at weeks 0 and 4 and then every eight weeks, an option set that matters for patients balancing convenience against infusion-center access.

The clinical backbone of the evidence rests on three pivotal double-blind randomized controlled trials. GO-RAISE and GO-AHEAD tested the subcutaneous formulation, the latter specifically in non-radiographic disease, while GO-ALIVE evaluated the intravenous route. In all three, golimumab significantly increased the proportion of patients achieving the primary endpoint, an ASAS20 response representing at least 20 percent improvement from baseline. But because contemporary practice has shifted toward the more demanding ASAS40 threshold and the Axial Spondyloarthritis Disease Activity Score, the review emphasizes those secondary endpoints. In GO-RAISE at 24 weeks, ASAS40 responses reached 43.5 percent with 50 milligrams and 54.3 percent with 100 milligrams of golimumab, against 15.4 percent for placebo. In GO-AHEAD at 16 weeks, 56.7 percent of golimumab-treated patients achieved ASAS40 versus 23.0 percent on placebo, and in GO-ALIVE the corresponding figures were 47.6 percent versus 8.7 percent. Disease activity scores fell significantly in both trials that measured them, and meaningful proportions of patients reached ASDAS inactive disease, a state the review argues should be treated as a legitimate therapeutic target. Extension trials lasting up to five years showed responses were maintained and the drug remained well tolerated, though the review is candid about limitations: small sample sizes, enrollment of patients with severe disease, and selection bias in uncontrolled extension phases all constrain generalizability.

Perhaps the most patient-relevant findings concern symptoms that clinical scores often compress into single numbers. Sleep disturbance, assessed in GO-RAISE with the Jenkins Sleep Evaluation Questionnaire, was severe at baseline across all groups, with scores in the 9-to-11 range on a 20-point scale. Golimumab cut those scores by roughly three points versus near-zero change on placebo at both 14 and 24 weeks, and the improvement correlated strongly with reductions in night pain, stiffness, fatigue, and functional indices. Back pain itself fell significantly in all three pivotal trials. The mechanism here is mechanical as much as molecular: patients with inflamed sacroiliac joints and spinal entheses wake repeatedly because lying still aggravates their symptoms, and movement to relieve pain fragments sleep, feeding daytime fatigue. Breaking that loop, the data suggest, delivers quality-of-life gains that go well beyond what a disease activity score alone captures.

The review’s post hoc analyses push further into the question of whether golimumab modifies the disease rather than merely suppressing symptoms. MRI analyses from GO-AHEAD showed significant resolution of sacroiliac joint inflammation using the Spondyloarthritis Research Consortium of Canada score, and GO-RAISE data demonstrated sustained reductions in spinal inflammation through week 104 that correlated with ASDAS and C-reactive protein levels. On structural damage, four years of GO-RAISE follow-up using the modified Stoke Ankylosing Spondylitis Spinal Score found no acceleration of radiographic progression after placebo patients crossed over to active treatment. The biomarker program, unique to the golimumab trials, produced a nuanced picture: a composite of 16 serum biomarkers fell significantly within weeks of treatment initiation, and responders showed distinct profiles of lower acute-phase reactants, yet individual biomarkers such as interleukin-6, leptin, complement component 3, and tissue inhibitor of metalloproteinase-1 correlated only weakly and inconsistently with disease activity, MRI changes, or structural progression. Vascular endothelial growth factor, once hypothesized as a predictor of new bone formation, proved to have no predictive value. The honest conclusion is that serum biomarkers, while mechanistically informative, do not yet offer reliable prognostic tools for individual patients.

Where the review genuinely distinguishes itself is in its synthesis of real-world evidence, an arena where randomized trials rarely venture. A Canadian registry study of 421 patients followed for up to seven years documented sustained improvements in disease activity and function, with enthesitis prevalence falling from 39.7 percent at baseline to 12.9 percent at two years. Korean claims data covering more than 34,000 patients showed golimumab carried the lowest adjusted hazard of incident acute anterior uveitis among the biologics compared, and its association with inflammatory bowel disease incidence was similar to no treatment at all, a meaningful safety signal given that uveitis and IBD are common extra-articular complications of the disease. Hemoglobin analyses pooled across five trials added another dimension, showing that golimumab significantly improved inflammation-associated anemia, raising hemoglobin by 1.4 grams per deciliter versus 0.2 on placebo in that subgroup.

Drug survival, the composite metric that quietly integrates efficacy, tolerability, and patient satisfaction, emerged as one of golimumab’s strongest suits. In the French RIC register, median retention on golimumab was 59 months, significantly longer than for adalimumab, etanercept, or certolizumab pegol. Danish nationwide registry data found the highest drug survival among biologics for golimumab relative to secukinumab, etanercept, adalimumab, certolizumab pegol, and infliximab, with hazard ratios for treatment failure ranging from 1.40 to 2.75 for the comparators. Taiwanese insurance data showed five-year discontinuation of 34.78 percent for golimumab versus 43.33 percent for etanercept and 46.62 percent for adalimumab, and a meta-analysis of 39 studies and nearly 32,500 patients placed golimumab’s drug survival at 72 percent at one year and 49 percent at five years, rising to 78 and 57 percent among patients starting it as a first biologic. Notably, two studies found that although adalimumab was prescribed more often as first-line therapy, golimumab first-line use delivered superior retention, challenging prescribing habits that default to older agents.

Safety findings address two longstanding anxieties around TNF inhibitors. In Korean and Slovenian real-world cohorts, no patients with a history of tuberculosis experienced reactivation on golimumab, and none of 103 patients with latent tuberculosis who received prophylaxis before treatment developed active disease, reinforcing that screening and prophylaxis effectively neutralize the risk, though vigilance remains warranted in endemic regions. Pregnancy data, though limited in absolute numbers, were similarly reassuring: among 134 infants with prenatal golimumab exposure in Nordic registries, there were no stillbirths or deaths, major congenital anomalies occurred in 4.5 percent of exposed infants, comparable to the 4.6 percent background rate in the general population, and first-year infection hospitalizations ran at 11 percent, matching comparator cohorts. European recommendations now permit TNF inhibitors throughout pregnancy, with the caveat that the risk of untreated maternal disease must be weighed against any fetal drug exposure.

Network meta-analyses provide the closest thing to head-to-head comparisons that currently exist, and they position golimumab favorably without crowning it definitively. Across three analyses encompassing thousands of patients, TNF inhibitors including golimumab tended to dominate the top efficacy rankings, with subcutaneous golimumab achieving the highest SUCRA score for ASAS20 response in one analysis of non-radiographic disease. The review cautions, however, that SUCRA rankings do not indicate whether differences between treatments are clinically meaningful, a high-ranking drug may outperform alternatives by trivial margins. Indirect comparisons carry inherently low certainty, and the absence of head-to-head trials remains a structural gap in the field.

Taken together, the evidence assembled in this review paints golimumab as an effective, safe, and durable option for axial spondyloarthritis, one whose benefits extend from MRI-visible inflammation to the bedroom, the workplace, and the pregnancy clinic. The authors’ overarching message is that reductions in disease activity sit at the hub of nearly every patient-centered improvement, from sleep and productivity to quality of life, and that achieving inactive disease should be the explicit goal of therapy. For a disease that only two decades ago was managed with little more than nonsteroidal anti-inflammatory drugs and physical therapy, the accumulation of trial, biomarker, and registry evidence around a single molecule illustrates how thoroughly modern immunology has reshaped what remission can look like for patients with axial spondyloarthritis.